Vicapsys Life Sciences, Inc.

Market Cap $224.50M
Debt $270.46K
Cash $53.53K
EV $224.72M
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$1.08M
EBIT	-$1.01M
ROA	-486%
Equity	-$1.33M
Growth Stability	1
PE	-207.89
PB	-168.31
Price/Cash	0
Debt/Equity	-0.2
Earnings Growth YoY	62%
Earnings Growth QoQ	77%
Market Cap	$224.50M

Assets	$208.49K
Total Debt	$270.46K
Cash	$53.53K
Shares Outstanding	32.07M
EV	224.72M
Working Capital	-1.33M
Current Ratio	0.14
Shares Growth 3y	9%
Equity Growth QoQ	22%
Equity Growth YoY	156%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Vicapsys Life Sciences Inc is a biotech company that is engaged in commercializing implantable medical products that incorporate VICAPSYN, inducing a zone of immuno-protection around devices and cells implanted in the human body. The product name VICAPSYN is the company's line of proprietary product candidates that is applied to transplantation therapies and related stem-cell applications in the transplantation field.

SEC Filings

Direct access to Vicapsys Life Sciences, Inc. (VICP) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2023
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2021
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Vicapsys Life Sciences, Inc. compare to its competitors?

Not enough data to generate a comparison chart between Vicapsys Life Sciences, Inc. and its competitors. Please check back later.

Peter Lynch's Chart

This chart shows the current pricing of Vicapsys Life Sciences, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Vicapsys Life Sciences, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Vicapsys Life Sciences, Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2019	12/2020	12/2021	12/2022	TTM
Net Margins	-	-	-	-	-
ROA	-	-190%	-40%	-1K%	-486%
ROE	-	171%	195%	104%	-

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2019	12/2020	12/2021	12/2022	TTM
Debt over FCF	-	-	-	-	-
Debt over Equity	-	-	-	-	-0.2
Growth Stability	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (-0.2)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2019	12/2020	12/2021	12/2022	CAGR 5Y
Revenue YoY growth	-	-	-	-	-
Earnings YoY growth	-	-51%	-69%	317%	-
Equity YoY growth	-	-249%	-73%	682%	-
FCF YoY growth	-	-	-	-	-